# Second-line rituximab–bendamustine versus rituximab–gemcitabine–oxaliplatin in diffuse large B-cell lymphoma in the real world

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/second-line-rituximab-bendamustine-versus-rituximab-gemcitabine-oxaliplatin-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Raluca Ionescu‐Ittu,Aijing Shang,Nancy Vander Velde,Annie Guérin,Yilu Lin,Lizheng Shi,Sherry Shi,Naseer Qayum |
| Citations | 13 |
| DOI | 10.2217/cer-2019-0062 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://www.futuremedicine.com/doi/pdf/10.2217/cer-2019-0062 |
| OpenAlex ID | https://openalex.org/W2971092198 |
| PMID | 31452397 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Yilu Lin](https://scholariq.org/researchers/yilu-lin/)

## Paper journal

- [Journal of Comparative Effectiveness Research](https://scholariq.org/journals/journal-of-comparative-effectiveness-research/)

## Paper primary topic

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Paper topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.